iPLATO Healthcare

iPLATO Healthcare Ltd, founded in 2006 in London, UK, focuses on providing a unified technology platform to optimize primary care. The company has undergone strategic pivots to enhance its offerings. In January 2022, iPLATO was acquired by Huma Therapeutics Limited, a portfolio company of Bayer AG, from YFM Venture Finance Limited.iPLATO's primary offerings center around a unified technology platform designed to enhance primary care and population health through innovative, multi-channel patient engagement. The core products include the myGP app, which enables health-conscious patients to manage their healthcare more effectively, and a suite of solutions that streamline patient pathways across fragmented healthcare systems. These offerings are deployed by NHS payers and utilized by a network of GP surgeries, aiming to empower millions of patients and caregivers. The solutions specifically target challenges such as health inequalities and the overburdening of healthcare services by facilitating better collaboration among clinicians and care professionals.9. The company's revenue model is structured around a combination of subscription services and partnerships with healthcare providers, including NHS entities and private GP practices. Clients pay for access to the platform and its capabilities, which include features like patient questionnaires, population health engagement tools, and digital front-door solutions. The company is exploring expansion into additional European markets, with strategic plans in place to target specific regions by the end of 2023.

1. Series A

   Mar 21, 2006

   Amount

   $0.4M

   Investors

   Locked